Griseofulvin

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 79, Issue , 2001, Pages 291-315

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011531579     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (109)

1. Albertini, S., Brunner, M. & Würgler, F.E. (1993) Analysis of the six additional chemicals for in vitro assays of the European Economic Communities' EEC aneuploidy programme using Saccharomyces cerevisiae D61.M and in vitro porcine brain tubulin assembly assay. Environ, mol. Mutag., 21, 180-192
2. Amacher, D.E. & Zelljadt, I. (1983) The morphological transformation of Syrian hamster embryo cells by chemicals reportedly nonmutagenic to Salmonella typhimurium. Carcinogenesis, 4, 291-295
3. American Hospital Formulary Service (2000) AHFS Drug Information® 2000, Bethesda, MD, American Society of Health-System Pharmacists [AHFSfirst CD-ROM]
4. Bourner, R.D.P., Parry, E.M. & Parry, J.M. (1998) Chemically induced aneuploidy: Investigations into chromosome specific effects in mitosis. Mutât. Res., 404, 191-197
5. British Pharmacopoeia Commission (1993) British Pharmacopoeia 1993, Vols I & II, London, Her Majesty's Stationery Office, pp. 316-317, 933-934
6. Bruce, R.W. & Heddle, J.A. (1979) The mutagenic activity of 61 agents as determined by the micronucleus, Salmonella, and sperm abnormality assay. Can. J. Genet. Cytol., 21,319-334
7. Budavari, S., ed. (2000) The Merck Index, 12th Ed., version 12:3, Whitehouse Station, NJ, Merck & Co. & Boca Raton, FL, Chapman & Hall/CRC [CD-ROM]
8. Cantoni, L., di Padova, C., Rovagnati, P., Ruggieri, R., Dal Fiume, D. & Tritapepe, R. (1983) Bile secretion and liver microsomal mixed function oxidase system in mice with griseofulvininduced hepatic protoporphyria. Toxicology, 27, 27-29
9. Capen, C.C. (2000) Comparative anatomy and physiology. In: L.E. Braverman & Utiger, R.D., eds, Werner and Inbars, The Thyroid. A Fundamental and Clinical Text, 8th Ed., Lippincott Williams & Wilkins, Philadelphia, pp. 20-42
10. CIS Information Services (2000a) Directory of World Chemical Producers (Version 2000.1), Dallas, TX [CD-ROM]
11. CIS Information Services (2000b) Worldwide Bulk Drug Users Directory (Version 2000), Dallas, TX [CD-ROM]
12. Council of Europe (1997) European Pharmacopoeia, 3rd Ed., Strasbourg, pp. 916-91
13. Curry, P.T., Reed, R.N., Martino, R.M. & Kitchin, R.M. (1984) Induction of sister-chromatid exchanges in vivo in mice by the mycotoxins sterigmatocystin and griseofulvin. Mutat. Res., 137, 111-115
14. De Matteis, F. (1966) Hypercholesterolemia and liver enlargement in experimental hepatic porphyria. Biochem. J., 98, 23C-25C
15. De Matteis, F. & Gibbs, A.H. (1975) Stimulation of the pathway of porphyrin synthesis in the liver of rats and mice by griseofulvin, 3,5-diethoxycarbonyI-l,4-dihydrocollidine and related drugs: Evidence for two basically different mechanisms. Biochem. J., 146, 285-287
16. De Matteis, F., Donnelly, A.J. & Runge, W.J. (1966) The effect of prolonged administration of griseofulvin in mice with reference to sex differences. Cancer Res., 26, 721-726
17. Denk, H., Gschnait, F. & Wolff, K. (1975) Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: A new experimental model for the study of hyalin formation. Lab. Invest., 32, 773-776
18. Denk, H., Eckerstorfer, R., Talcott, R.E. & Schenkman, J.B. (1977) Alteration of hepatic microsomal enzymes by griseofulvin treatment of mice. Biochem. Pharmacol, 26, 1125-1130
19. Denk, H., Abdelfattah-Gad, M., Eckerstorfer, R. & Talcott, R.E. (1980) Microsomal mixedfunction oxidase and activities of some related enzymes in hyperplastic nodules induced by long-term griseofulvin administration in mouse liver. Cancer Res., 40, 2568-2573
20. Denk, H., Kalt, R., Abdelfattah-Gad, M. & Meyer, U.A. (1981) Effect of griseofulvin on 5aminolevulinate synthase and on ferrochelatase in mouse liver neoplastic nodules. Cancer Res., 41, 1535-1538
21. Denk, H., Bernklau, G & Krepier, R. (1984) Effect of griseofulvin treatment and neoplastic transformation on transglutaminase activity in mouse liver. Liver, 4, 208-213
22. Esptein, S.S., Andrea, J., Joshi, S. & Mantel, N. (1966) Hepatocarcinogenicity of griseofulvin following parental administration to infant mice. Cancer Res., 27, 1900-1906
23. Fahmy, M.A. & Hassan, N.H.A. (1996) Cytogenetic effect of griseofulvin in mouse spermatocytes. J. appl. Toxicol, 16, 177-183
24. Food and Drug Administration (2000) USFDA Greenback of 'PDA Approved Animal Products, Rockville, MD
25. Friedman, GD. & Ury, H.K. (1980) Initial screening for carcinogenicity of commonly used drugs. J. natl Cancer Inst., 65, 723-733
26. Friedman, GD. & Ury, H.K. (1983) Screening for possible drug carcinogenicity: Second report of findings. J. natl Cancer Inst., 71, 1165-1175
27. Gennaro, A.R. (1995) Remington: The Science and Practice of Pharmacy, 19th Ed., Vol. II, Easton, PA, Mack Publishing Co., p. 1329
28. Gershbein, L.L. & Pedroso, A.F. (1985) Action of drugs and chemical agents on rat liver regeneration. Drug cliem. Toxicol.,8, 125-143
29. Gibson, O.P., Aardema, M.J., Kerckaert, GA., Carr, GJ., Brauninger, R.M. & LeBoeuf, R.A. (1995) Detection of aneuploidy-inducing carcinogens in the Syrian hamster embryo (SHE) cell transformation assay. Mittat. Res., 343, 7-24
30. Gschnait, F., Konrad, K., Hönigsmann, H., Denk, H. & Wolff, K. (1975) Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals. J. invest. DermatoL, 65, 290-299
31. Hammond, O.K. & Strobel, H.W. (1990) Human colon tumor cell line LS174T drug metabolizing system. Mol. Cell Biochem., 93, 95-105
32. Holley, A., King, L.J., Gibbs, A.H. & De Matteis, F. (1990) Strain and sex differences in the response of mice to drugs that induce protoporphyria: Role of porphyrin biosynthesis and removal. J. biochem. Toxicol.,5, 175-182
33. I ARC ( 1976) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Vol. 10, Some Naturally Occurring Substances, Lyon, lARCPress, pp. 153-161
34. IARC (1987) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes I to 42, Lyon, IARCPress, pp. 64, 391
35. IARC (1999) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 71, Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide, Lyon, lARCPress, pp. 1181-1187
36. Inafuku, K., Takamiyagi, A., Oshiro, M., Kinjo, T., Nakashima, Y. & Nonaka S., (1999) Alteration of mRNA levels of 5-aminolevulinic acid syntase, ferrochelatase and heme oxygenase-1 in griseofulvin induced protoporphyria mice. J. dermatol. Sci., 19, 189-198
37. Inoue, H., Baba, H., Awano, K. & Yoshikawa, K. (1995) Genotoxic effect of griseofulvin in somatic cells of Drosophila melanogaster. Mutât. Res., 343, 229-234
38. Instituto National de Farmacia e do Medicamento (2000) Lisbon
39. Irish Medicines Board (2000) Dublin
40. Kaiweit, S., Utesch, D., von der Hude, W. & Madie, S. (1999) Chemically induced micronucleus formation in V79 cells -Comparison of three different test approaches. Mutât. Res., 439, 183-190
41. Kenner, L., Zatloukai, K., Stumptner, C., Eferl, R. & Denk, H. (1999) Altered microtubule-associated Tau messenger RNA isoform expression in livers of griseofulvin- and 3,5-diethoxycarbonyl-l,4-dihydrocollidine-treated mice. Hepatology, 29, 793-800
42. Kinsella, A.R. (1982) Elimination of metabolic co-operation and the induction of sister chromatid exchanges are not properties common to all promoting or co-carcinogenic agents. Carcinogenesis, 3, 499-503
43. Klein, M.F. & Beall, J.R. (1972) Griseofulvin: A teratogenic study. Science, 175, 1483-1484
44. Knasmüller, S., Parzefall, W., Helma, C., Kassie, F., Ecker, S. & Schuhe-Hermann, R. (1997) Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment. Crit. Rev. Toxicol, 27, 495-537
45. Kolachana, P. & Smith, M.T. (1994) Induction of kinetochore-positive micronuclei in human lymphocytes by the anti-fungal drug griseofulvin. Mutât. Res., 322, 151-159
46. König, E., Berthold, K., Hienz, H.A. & Brittinger, G (1969/70) Griseofulvin and chronic granulocytic leukaemia. Helvet. med. Acta, 35, 103-107
47. Lapina, I.Z., Leshchenko, V.M., Bendikov, E.A. & Petrakov, A.V. (1989) [Detoxifying function of the liver in patients with rubromycosis during treatment with antimycotics.] Vestn. Dermatol. Venerol., 4, 51-54 (in Russian)
48. Léonard, A., Poncelet, F., Grutman, G, Carbonelle, E. & Fabry, L. (1979) Mutagenicity tests with griseofulvin. Mutât. Res., 68, 225-234
49. Lide, D.R. & Milne, GW.A. (1996) Properties of Organic Compounds, Version 5.0, Boca Raton, FL, CRC Press, Inc. [CD-ROM]
50. Lin, C.-C. & Symchowicz, S. (1975) Absorption, distribution, metabolism and excretion of griseofulvin in man and animals. Drug Metab. Rev., 4, 75-95
51. 14C]griseofulvin in the mouse. J. Pharm. Pharmacol., 24, 911-913
52. l4C-griseofu!vin in man. J. Pharmacol. exp. Ther., 187, 415-422
53. Lin, C.-C., Chang, R., Casmer, C. & Symchowicz, S. (1973b) Effects of phénobarbital, 3-methylcholanthrene and griseofulvin on the O-demethylation of griseofulvin by liver microsomes of rats and mice. Drug Metab. Disposition, 1, 611-618
54. MacLeod, J. & Nelson, W.O. (1959) Griseofulvin and human spermatogenesis. Proc. Soc. exp. Med. Biol, 102, 259-260
55. Mailhes, J.B., Marchetti, F. & Aardema, M.J. (1993) Griseofulvin-induced aneuploidy and meiotic delay in mouse oocytes: Effect of dose and harvest time. Mutât. Res., 300, 155-163
56. Martin, F.H. & Tsuk, A.G (1982) Therapeutic Compositions with Enhanced Unavailability (Patent No. 4,344,934). US Patent assignee: New York, American Home Products Corporation
57. Medical Economics Co. (1999a) Fulvicin P/G 165 & 330 tablets (Schering Corp.). In: PDR®: Physicians'Desk Reference, 53rd Ed., Montvale, NJ, Medical Economics Data Production Co. [MicroMedex Online]
58. Medical Economics Co. (1999b) Fulvicin P/G tablets (Schering Corp.). In: PDR®: Physicians' Desk Reference, 53rd Ed., Montvale, NJ, Medical Economics Data Production Co. [MicroMedex Online]
59. Medical Economics Co. (1999c) Grifulvin V tablets microsize and oral suspension microsize (ortho dermatological). In: PDR®: Physicians ' Desk Reference, 53rd Ed., Montvale, NJ, Medical Economics Data Production Co. [MicroMedex Online]
60. Medical Economics Co. (1999d) Gris-PAG tablets (Allergan). In: PDR®: Physicians'Desk Reference, 53rd Ed., Montvale, NJ, Medical Economics Data Production Co. [MicroMedex Online]
61. Medical Products Agency (2000) Uppsala
62. Migliore, L., Cocchi, L. & Scarpato, R. (1996) Detection of the centromere in micronuclei by fluorescence in situ hybridisation: Its application to the human lymphocyte micronucleus assay after treatment with four suspected aneugens. Mutagenesis, 11, 285-290
63. Nagao, Y., French, B.A., Cai, Y., French, S.W. & Wan, Y.-J.Y. (1998) Inhibition of PPARo/PXRa-mediated direct hyperplasia pathways during griseofulvin-induced hepatocarcinogenesis. J. cell. Biochem., 69, 189-200
64. National Institute for Occupational Safety and Health (2000) National Occupational Exposure Swvey 1981-83, Cincinnati, OH, Department of Health and Human Services, Public Health Service
65. Nimni, M.E., Ertl, D. & Oakes, R.A. (1990) Distribution of griseofulvin in the rat: comparison of the oral and topical route of administration. J. pharm. Pharmacol, 42, 729-731
66. Norwegian Medicinal Depot (2000) Oslo
67. Pirrung, M.C., Brown, W.L., Rege, S. & Laughton, P. (1991) Total synthesis of (+)-griseofulvin. J. Am. chem. Soc., 113, 8561-8562
68. Polo, C.F., Buzaleh, A.M., Vazquez, E.S., Afonso, S.G, Navone, N.M. & Del Carmen Batlle, A.M. (1997) Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Gen. Pharmacol., 29, 207-210
69. Preisegger, K.H., Stumptner, C., Riegelnegg, D., Brown, P.C., Silverman, J.A., Thorgeirsson, S.S. & Denk, H. (1996) Experimental Mallory body formation is accompanied by modulation of the expression of multidrug-resistance genes and their products. Hepatology, 24, 248-252
70. Qinghua, S., Schmid, T.E. & Adler, I.-D. (1999) Griseofulvin-induced aneuploidy and meiotic delay in male mouse germ cells: Detected by using conventional cytogenetics and threecolor FISH. Mutat. Res., 441, 181-190
71. Rimington, C., Morgan, P.N., Nicholls, K., Everall, J.D. & Davies, R.R. (1963) Griseofulvin administration and porphyrin metabolism. A survey. Lancet, 13, 318-322
72. Rodriguez-Arnaiz, R. & Aranda, J.H. (1994) Metabolic activation of four drugs in the eye mosaic assay measuring principally mitotic recombination in Drosophila melanogaster: Differences in strain susceptibility and route of exposure. Mutât. Res., 305, 157-163
73. Rowland, M., Riegelman, S. & Epstein, W.L. (1968) Absorption kinetics of griseofulvin in man. J. pharm. Sci., 57, 984-989
74. Royal Pharmaceutical Society of Great Britain (2000) Martindale, The Extra Pharmacopoeia, 13th Ed., London, The Pharmaceutical Press [MicroMedex Online]
75. Rustia, M. & Shubik, P. (1978) Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. Br. J. Cancer, 38, 237-249
76. Sadtler Research Laboratories (1995) Sadtler Standard Spectra, 1981-1995 Supplementary Alphabetical Index, Philadelphia, PA, p. 388
77. Salonpää, P., Krause, K., Pelkonen, O. & Raunio, H. (1995) Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Arch. Pharmacol, 351, 446-452
78. Schardein, J.L. (1993) Chemically Induced Birth Defects, 2nd Ed., New York, Marcel Dekker, p. 374
79. Scott, F.W., De LaHunta, A., Schultz, R.D., Bistner, S.I. & Riis, R.C. (1975) Teratogenesis in cats associated with griseofulvin therapy. Teratology, 11, 79-86
80. Seelbach, A., Fissler, B., Strohbusch, A. & Madie, S. (1993) Development of a modified micronucleus assay //; vitro for detection of aneugenic effects. Toxicol. In Vitro, 7, 185-193
81. Sehgal, A., Osgood, C. & Zimmering, S. (1990) Aneuploidy in Drosophila. III. Aneuploidogens inhibit in vitro assembly of Taxol-purified Drosophila microtubules. Environ. Mol. Mtitagenesis, 16,217-224
82. Seif, R. (1980) Factors which disorganize microtubules or microfilaments increase the frequency of cell transformation by polyoma virus. J. Virol, 36, 421-428
83. Selby, J.V., Friedman, GD. & Fireman, B.H. (1989) Screening prescription drugs for possible carcinogenicity: Eleven to fifteen years of follow-up. Cancer Res., 49, 5736-5747
84. Shimoyama, T. & Nonaka, S. (1987) Biochemical studies on griseofulvin induced protoporphyria. Ann. N.Y. Acad. Sci., 514, 160-169
85. Sloboda, R.D., Van Blaricom, G, Creasey, W.A., Rosenbaum, J.L. & Malawista, S.E. (1982) Griseofulvin: Association with tubulin and inhibition of in vitro microtubule assembly. Biochem. biophys. Res. Connu., 105, 882-888
86. Slonitskaya, N.N. (1969) Teratogenic effect of griseofulvin-forte on rat foetus. Antibiotiki, 14, 44-48
87. Society of Japanese Pharmacopoeia (1996) The Japanese Pharmacopoeia JP XIII, 13th Ed., Tokyo, p. 414
88. Spanish Medicines Agency (2000) Madrid
89. Steelman, R.L. & Kocsis, J.J. (1978) Determination of the teratogenic and mutagenic potential of griseofulvin (Abstract). Toxicol. appl. Pharmacol., 45, 343-344
90. Stopper, H., Eckert, I., SchifTmann, D., Spencer, D.L. & Caspary, W.J. (1994) Is micronucleus induction by aneugens an early event leading to mutagenesis? Mutagenesis, 9, 411-416
91. Suter, W. & Jaeger, I. (1982) Comparative evaluation of different pairs of DNA repair-deficient and DNA repair-proficient bacterial tester strains for rapid detection of chemical mutagens and carcinogens. Mutât. Res., 97, 1-18
92. Swiss Pharmaceutical Society, ed. (2000) Index Nominwn, International Drug Directory, 16th Ed., Stuttgart, Medpharm Scientific Publishers [MicroMedex Online]
93. 14C metabolism in the rat and rabbit. Biochem. Pharmacol, 16, 2405-2411
94. Townley, E.R. (1979) Griseofulvin. Anal. Profiles Drug Sitbst., 8, 219-249
95. Ueno, Y. & Kubota, K. (1976) DNA-attacking ability of carcinogenic mycotoxins in recombination-deficient mutant cells of Bacillus subtilis. Cancer Res., 36, 445-451
96. US Pharmacopeial Convention (1998) USP Dictionary of USAN and International Drug Names, 1998, Rockvilie, MD
97. US Pharmacopeial Convention (1999) The 2000 US Pharmacopeia, 24th Rev.The National Formulary, 19th Rev., Rockvilie, MD, pp. 788-791
98. Venier, P., Montini, R., Zordan, M., Clonfero, E., Paleologo, M. & Levis, A.G (1989) Induction of SOS response in Escherichia coli strain PQ37 by 16 chemical compounds and human urine extracts. Mutagenesis, 4, 51-57
99. Vesselinovitch, S.D. & Mihailovich, N. (1968) The inhibitory effect of griseofulvin on the 'promotion' of skin carcinogenesis. Cancer Res., 28, 2463-2465
100. Vidai (2000) Le Dictionnaire, 76th Ed., Paris, Editions du Vidai
101. Vincent, S.H., Smith, A.G & Muller-Eberhard, U. (1989) Modulation of hepatic heme-binding Z protein in mice by the porphyrogenic carcinogens griseofulvin and hexachloroberizene. Cancer Lett., 45, 109-114
102. Weber, K., Wehland, J. & Herzog, W. (1976) Griseofulvin interacts with microtubules both in vivo and in vitro. J. mol. Biol., 102, 817-829
103. Wehland, J., Herzog, W. & Weber, K. (1977) Interaction of griseofulvin with microtubules, microtubule protein and tubulin. J. mol. Biol., Ill, 329-342
104. Wehner, F.C., Thiel, P.G, Van Rensburg, S.J. & Demasius, I.P.C. (1978) Mutagenicity to Salmonella typhiimirhtm of some Aspergillus and Pénicillium mycotoxins. Mutat. Res., 58,193-203
105. Williams, M. & Simonet, L. (1986) Effects of griseofulvin on enzymes associated with phase 1 and II of drug metabolism. Biochem. Pharmacol., 35, 2630-2632
106. Williams, M. & Simonet, L. (1988) In vivo suppression of stearyl CoA desaturase activity by griseofulvin: Evidence against the involvement of lipid peroxidation. Toxicol. appl. Pharmacol., 96, 541-549
107. Williams, J.A. & Wolff, J. (1970) Possible role of microtubules in thyroid secretion. Proc. natl Acad. Sci. USA, 67, 1901-1908
108. Williams, GM., Mori, H. & McQueen, C.A. (1989) Structure-activity relationships in the rat hepatocyte DNA-repair test for 300 chemicals. Mutât. Res., 221, 263-286
109. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T. & Mortelmans, K. (1992) Salmonella mutagenicity tests. V. Results from the testing of 311 chemicals. Environ, mol. Mutag., 19 (Suppl. 21), 2-141